Piers Whitehead joins Neovacs
This article was originally published in Scrip
Neovacs, a French biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, has named Piers Whitehead vice-president of corporate development. He has more than 15 years' experience in the life sciences industry, having previously served as vice-president of business and corporate development for VaxGen. Before that, he was a vice-president at Mercer Management Consulting, where he headed the firm's San Francisco office.